Lupin receives approval from USFDA for Brexpiprazole Tablets
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
ELL will be the preferred source of supply for some the key Raw Materials to VPPL at "Arm's Length" transaction.
He is Proficient in overseeing and leading teams for running successful business operations
This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
Patients will no longer need to travel abroad for treatment of acute cardiac diseases
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
Subscribe To Our Newsletter & Stay Updated